Effect of Antisense Oligodeoxynucleotide Directed to NF-κB-RelA on Bcl-x_L mRNA in Extended Drug Resistance Leukemia Cell Line HL- 60/E6

To explore the effect of NF κB on bcl x gene transcription in extended drug resistance leukemia cell line HL 60/E6, drug resistant subline HL 60/E6 was derived by intermittently exposing HL 60 cells to 6 ng/ml epirubicin. Indirect immunofluorescence was used to demonstrate the location of NF κB RelA in HL 60/E6 cells. FCM analysis and RT PCR were used to detect the efficiency of liposome mediated ODN transfection and the change of bcl x L mRNA levels after 5 μmol/L phosphorothioate (PS) derivatized antisense (AS) oligodeoxynucleotide (ODN) directed to RelA was transferred into HL 60/E6 cells. The results showed that RelA remained persistently active and located at the nuclei of HL 60/E6 cells,but in the cytoplasm of HL 60 cells, the efficiency of liposome mediated ODN transfection was significantly higher than that of null ODN ( P <0.01 in 4 h, 6 h, 12 h, 24 h). Exposure of HL 60/E6 cells to 5 μmol/L AS PS ODN directed to RelA led to a maximal 40 % decline of bcl x L mRNA levels within 8 h. The inhibition rate of bcl x L mRNA was (15±1.79) %, (28±2.34) %, (40±3.47) %, (20±1.54) % in 4 h, 6 h, 8 h, 15 h, respectively, but it was less than 15 % in control group. It was concluded that NF κB was involved in regulating bcl x transcription. It was suggested that NF κB was an important factor for drug resistance in leukemia cells.

Glycogen Synthase Kinase 3β Inhibitor (2'Z,3'E)-6-Bromo-indirubin-3'-Oxime Enhances Drug Resistance to 5-Fluorouracil Chemotherapy in Colon Cancer Cells

Objective： To explore the effects and mechanism of glycogen synthase kinase 3β （GSK-313） inhibitor （2＇Z,3＇E）-6-bromo-indirubin-3＇-oxime （BIO） on drug resistance in colon cancer cells. Methods： The colon cancer SW480 and SW620 cells were treated with BIO, 5-fluorouracil （5-FU） and BIO/5-FU, separately. Cell cycle distribution, apoptosis level and efflux ability of rhodamine 123 （Rh123） were detected by flow cytometry. The protein expressions of P-glycoprotein （P-gp）, multidrug resistance protein 2 （MRP2）, thymidylate synthase （TS）, β-catenin, E2F-1 and βcl-2 were detected by Western blot. β-catenin and P-gp were stained with double immunofluorescence and observed under a confocal microscope. Results： BIO up-regulated β-catenin, P-gp, MRP2 and TS, enhanced the efflux ability of Rh123, decreased Bcl-2 protein and gave the opposite effect to E2F-1 protein in SW480 and SW620 ceils. Furthermore, BIO significantly inhibited cell apoptosis, increased S and G2/M phase cells, and reduced the cell apoptosis induced by 5-FU in SW480 cells, whereas the effects were slight or not obvious in SW620 cells. Conclusion： GSK-3β was involved in drug resistance regulation, and activation of β-catenin and inhibition of E2F-1 may be the most responsible for the enhancement of 5-FU chemotherapy resistance induced by GSK-β inhibitor β10 in colon cancer.

基于美国FAERS数据库的多黏菌素E相关药品不良事件信号挖掘研究

目的:挖掘多黏菌素E的药品不良事件(ADE)信号,识别出潜在的不良反应,为临床合理用药提供依据。方法:采用比例失衡法(ROR),对美国食品药品监督管理局不良事件报告系统(FAERS)数据库中2013年10月1日至2023年10月1日的所有多黏菌素E相关ADE报告进行信号挖掘。分析报告病例的基本情况;映射得到对应的系统器官分类(SOC),并与药品说明书记录的不良反应进行对比;对不同适应证患者的首选术语(PT)进行分析。结果:共检索得到的1432例次报告事项,挖掘到140个以多黏菌素E为怀疑药物的ADE信号。其中涉及21种SOC,主要为全身性疾病及给药部位各种反应(381例次,占26.61%),其次为肾脏及泌尿系统疾病(168例次,占11.73%)和呼吸系统、胸及纵隔疾病(125例次,占8.73%)。报告例次数排序靠前的ADE信号涉及耐药、急性肾损伤、病原体耐药等PT,多器官功能不全综合征、囊性纤维化等PT未被药品说明书收录;信号强度排序靠前的ADE信号涉及胆石性肠梗阻、巴特综合征、非血小板减少性紫癜等PT,且上述3种PT均未被药品说明书收录。结论:对基于美国FAERS数据库的多黏菌素E相关ADE信号进行挖掘和评价,可为临床安全用药提供依据。

Isolation and Identification and Drug Resistance Analysis of Avian Escherichia coli and In Vitro Competition with Lactobacillus

[Objective]The paper was to understand the resistance of commonly used clinical antibiotics to avian Escherichia coli and the inhibition of lactobacillus against pathogenic E.coli.[Method]The strain was isolated and identified by SS medium culture,microscope examination,PCR amplification and biochemical test,and the sensitivity of avian E.coli to eight antibiotics was determined by disk diffusion method.Twelve strains of avian E.coli and one strain of lactobacillus were divided into five group using in vitro liquid culture method,namely simultaneous mixed culture group of lactobacillus and E.coli,first colonization group of E.coli,first colonization group of lactobacillus,E.coli control group and lactobacillus control group,for competitive inhibition test between E.coli and lactobacillus.[Result]Totally 34 strains with similar characteristics to E.coli strains were preliminarily screened;the target band amplified by PCR was 293 bp,which was consistent with the expected size.The isolated strain could decompose maltose,sucrose,lactose,glucose,arabinose,mannitol and sorbitol;the nitrate reduction test was positive,while citrate and V-P test was negative,consistent with the biochemical characteristics of E.coli.The resistance rate of the isolates to cefalexin and tylosin was over 65%,and that to enrofloxacin and doxycycline was up to 50%;the isolates were more sensitive to apramycin,tilmicosin,neomycin and colistin,and the total resistance rate was below 15%.The inhibitory effects of mixed culture of lactobacillus and E.coli against E.coli was better than first colonization of lactobacillus at 24 h;the inhibitory effects of first colonization of lactobacillus against E.coli was better than that of mixed culture of lactobacillus and E.coli at 36 h;the inhibitory effects of mixed culture of lactobacillus and E.coli against E.coli was the best at 48 h.[Conclusion]The isolated strains of E.coli were generally resistant to eight commonly used antibiotics.Lactobacillus could inhibit the growth of avian E.coli in vitro,and first colonization of lactobacillus received the best effort.

天然产物EM-E-11-4逆转人口腔上皮癌细胞KBV_(200)多药耐药作用及其机制

目的考察无毒浓度千金烷二帖化合物EM-E-11-4对P-糖蛋白(P-glycoprotein,P-gp)介导人口腔上皮癌多药耐药(multi-drug resistance,MDR)的逆转作用并检测其对P-gp功能的影响。方法MTT比色法测定EM-E-11-4对人口腔上皮癌KB及其具有多药耐药株表型的KBV_(200)细胞的细胞毒活性,采用维拉帕米为参比药,非细胞毒剂量EM-E-11-4(2.5、5、10μmol·L^(-1))与3种常用抗癌药合用考察其逆转肿瘤多药耐药的作用,并计算逆转倍数。EME-11-4对P-gp的转运功能采用阿霉素蓄积实验检测。EM-E-11-4对基础与维拉帕米诱导的P-gp ATPase活性采用P-gp-GloTM试剂盒检测。结果EM-E-11-4能够有效逆转P-gp介导的KBV_(200)的多药耐药,并具有良好的剂量依赖关系。10μmol·L^(-1)EM-E-11-4能够逆转KBV_(200)细胞对紫杉醇、长春新碱和阿霉素3种抗癌药物的耐药作用,逆转倍数分别为33.8、36.4、20.1。无细胞毒作用的EM-E-11-4对P-gp的转运功能有显著抑制作用,并且能够增加阿霉素在肿瘤细胞内的蓄积,具有良好的浓度依赖性。同时,EM-E-11-4能明显抑制维拉帕米刺激的重组P-gp的ATPase活性。结论EM-E-11-4能逆转P-gp介导的肿瘤多药耐药,其作用机制与抑制P-gp的转运功能有关,为其临床治疗口腔上皮癌肿瘤多药耐药提供了理论依据。

熊去氧胆酸联合维生素E治疗抗肿瘤药物所致急性药物性肝损伤的临床疗效分析

目的:探讨熊去氧胆酸联合维生素E治疗抗肿瘤药物所致急性药物性肝损伤(ADILI)的临床疗效。方法:选取2022年8月至2023年8月收集的104例因抗肿瘤药物所致的ADILI患者,根据不同治疗方案将其分为对照组和研究组,各52例,对照组接受异甘草酸镁治疗,在此基础上,研究组接受熊去氧胆酸联合维生素E治疗,比较两组肝功能指标、炎症指标、T淋巴细胞指标及不良反应。结果:治疗后,研究组血清AST、ALT、TBiL水平均低于对照组(均P<0.05);治疗后,研究组血清TNF-α、MIF、IL-6水平及NO含量均低于对照组(均P<0.05);治疗后,研究组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于对照组,CD8^(+)低于对照组(均P<0.05);两组并发症发生率(21.15%vs15.38%)比较无统计学意义(P>0.05)。结论:熊去氧胆酸联合维生素E可改善抗肿瘤药物所致ADILI患者的肝功能,还可控制其炎症反应,提高机体免疫功能,且安全性较高。

Redox-responsive biocompatible nanocarriers based on novel heparosan polysaccharides for intracellular anticancer drug delivery

Heparosan is a natural precursor of heparin biosynthesis in mammals. It is stable in blood circulation but can be degraded in lysosomes, showing good biocompatibility and long circulation features. So heparosan can be designed as anticancer drug carriers to increase tumor selectivity and improve the therapeutic effect. A novel redox-sensitive heparosancystamine-vitamin E succinate(KSV) micelle system was constructed for intracellular delivery of doxorubicin(DOX). Simultaneously, the redox-insensitive heparosan-adipic acid dihydrazide-vitamin E succinate copolymer(KV) was synthesized as control. DOX-loaded micelles(DOX/KSV) with an average particle size of 90–120 nm had good serum stability and redox-triggered depolymerization. In vitro drug release test showed that DOX/KSV micelles presented obvious redox-triggered release behavior compared with DOX/KV. Cytotoxicity and cell uptake were investigated using MGC80-3 tumor cells and COS7 fibroblast-like cells. The cell survival rate of blank micelles was more than 90%, and the cytotoxicity of DOX/KSV in MGC80-3 cells was higher than in COS7 cells, indicating that the carrier has better biocompatibility and less toxicity side effect. The cytotoxicity of DOX/KSV against MGC80-3 cells was significantly greater than that of free DOX and DOX/KV. Furthermore, compared with DOX/KV in MGC80-3 cells, DOX/KSV micelles uptook more anticancer drugs and then released DOX faster into the cell nucleus. The micelles were endocytosed by multiple pathways, but clathrin-mediated endocytosis was the main pathway. Therefore, heparosan polysaccharide could be a potential option as anticancer carrier for enhancing efficacy and mitigating toxicity.

Inhibitory effects of miRNA-200c on chemotherapy-resistance and cell proliferation of gastric cancer SGC7901/DDP cells

Background and Objective: miRNA-200c can not only inhibit the aggressiveness of cancer cells but also increase the sensitivity of cells to antitumor drugs. However, some mechanisms are still unclear. Recent researches revealed that E-cadherin is more than an inhibitor of metastasis, and it also plays important roles in reversing drug resistance. We had previously found that miRNA-200c could not only induce the expression of E-cadherin but also increase the sensitivity of gastric cancer SGC7901/DDP cells to cisplatin (DDP). This study aimed to explore the effects of miRNA-200c on biological characteristics of SGC7901/DDP cells and the roles of E-cadherin in the regulatory pathway of miRNA-200c. Methods: SGC7901/DDP cells and its parental cell line SGC7901 cells were transfected with miRNA-200c precursor (Pre-200c) and E-cadherin siRNA, respectively. Real-time RT-PCR was used to detect miRNA-200c expression after transfection with Pre-200c in SGC7901/DDP cell line. Drug sensitivities to DDP, 5-fluorouracil (5-FU), paclitaxel, and adriamycin (ADR) after transfection were tested using MTT assay. The proliferation of SGC7901/DDP cells was also detected after transfection. The protein changes of E-cadherin, Bax, and Bcl-2 after transfection were detected by Western blot. Results: The miRNA-200c expression in SGC7901/DDP cells after transfection of Pre-200c was 7.128 ± 0.159 times of that in negative control (P < 0.05). The IC50 of DDP, 5-FU, paclitaxel, and ADR in Pre-200c-transfected group were significantly lower than that in negative control group (P < 0.05). Compared to the control group, cell proliferation was significantly decreased (P < 0.05). The relative protein expressions of E-cadherin and Bax in Pre-200c-transfected group were significantly higher than those in negative control group (P < 0.05), whereas Bcl-2 was significantly lower than that in control (P < 0.05). Additionally, E-cadherin protein expression was significantly inhibited after transfected with E-cadherin siRNA in SGC7901 cells. The Bax protein expression was significantly down-regulated by E-cadherin siRNA (P < 0.05), whereas the Bcl-2 expression was significantly up-regulated (P < 0.05). Conclusion: miRNA-200c can indirectly regulate apoptosis through E-cadherin in SGC7901/DDP cells, which may be a possible mechanism of miRNA-200c in reversing drug resistance and inhibiting proliferation.

新疆阿克苏地区猪场optrA/lsa(E)阳性粪肠球菌的耐药情况及传播特点分析

【目的】了解新疆阿克苏地区猪源粪肠球菌中optrA和lsa(E)的流行及传播特点,并探明optrA和lsa(E)阳性粪肠球菌的耐药情况,为评估两个耐药基因对公共卫生的影响和危害提供科学依据。【方法】对新疆农业大学兽医药理学实验室分离保存的322株粪肠球菌采用PCR的方法进行optrA和lsa(E)筛查,根据CLSI推荐药物及方法采用琼脂稀释法测定optrA和lsa(E)阳性菌株对氨苄西林、红霉素、泰乐菌素、四环素、多西环素、利奈唑胺、氟苯尼考、万古霉素、左氧氟沙星、恩诺沙星、庆大霉素和沃尼妙林的最小抑菌浓度(MIC)并进行耐药判定,利用PCR方法筛查相应的耐药基因,包括ermA、ermB、ermC、fexA、fexB、tet(K)、tet(L)、tet(M)、aac(6’)-le-aph(2")-Ia和cfr。选取31株不同来源的optrA和lsa(E)阳性粪肠球菌进行MLST分子分型和接合转移试验。【结果】共193株粪肠球菌检出optrA和/或lsa(E),其中38株optrA和lsa(E)共存,9株仅携带optrA,146株仅携带lsa(E)。这193株粪肠球菌对红霉素、泰乐菌素、四环素、多西环素、庆大霉素和沃尼妙林的耐药率均达到100%,虽然optrA检出率远低于lsa(E),但optrA阳性菌株总体耐药程度明显高于仅携带lsa(E)的菌株以及optrA、lsa(E)双阴性的菌株,其耐药基因的检出结果也呈现相同趋势。optrA和lsa(E)共存和仅携带optrA菌株的多重耐药谱集中在8耐和10耐,占比分别为84.6%和100.0%,而仅携带lsa(E)的菌株和optrA、lsa(E)双阴性菌株的多重耐药谱主要集中在6—8耐,占比为89.4%和90.7%。进一步分析optrA、lsa(E)与耐药性之间的关系发现,耐药较为严重的猪场optrA和lsa(E)的检出率也相对较高。耐药基因检出结果显示:193株菌均不同程度地携带ermB、ermC、tet(K)、tet(L)、tet(M)、aac(6’)-Ie-aph(2")-Ia、fex(A),并且optrA、lsa(E)共存的菌株及仅携带optrA菌株的耐药基因检出率总体上也高于仅携带lsa(E)的菌株和optrA、lsa(E)双阴性菌株。MLST和接合转移试验结果提示,optrA/lsa(E)菌株遗传环境复杂、可能既存在克隆传播又存在水平转移的现象。【结论】新疆阿克苏地区猪源粪肠球菌中optrA和lsa(E)的高携带率以及高耐药水平表明该地区耐药形势严峻,对当地生猪养殖业甚至于公共卫生安全都造成威胁,应及时采取措施以防控耐药性的进一步发展。

多黏菌素E甲磺酸钠治疗多重耐药鲍曼不动杆菌肺炎的效果观察

目的探讨多黏菌素E甲磺酸钠治疗多重耐药鲍曼不动杆菌肺炎的效果,以期为临床相关治疗提供参考。方法本研究选取2021年12月—2022年2月在华中科技大学同济医学院附属同济医院重症监护室收治的3名患者为研究对象。对3例患者均使用多黏菌素E甲磺酸钠联合其他药物治疗。收集多重耐药鲍曼不动杆菌感染患者使用多黏菌素E甲磺酸钠后的一系列感染相关指标及器官功能变化资料。结果经过治疗,患者最终均取得了良好的治疗效果。结论多黏菌素E甲磺酸钠治疗多重耐药鲍曼不动杆菌肺炎的临床疗效可靠,但与有潜在肾功能损害的药物联合使用时应慎重选择。

基于文献计量的多黏菌素E治疗药物监测相关研究热点和未来趋势分析

目的基于Web of Science数据库,利用文献计量学和可视化分析探索多黏菌素E治疗药物监测(TDM)相关研究的现状、热点和发展趋势。方法收集Web of Science核心数据库2012至2022年收录的多黏菌素E TDM相关研究的文献,应用机器学习和可视化工具,包括VOSviewer软件、书目共现分析系统和图形聚类工具包进行文献计量学分析。结果本研究共纳入713篇文献,2012至2022年文献的发表量有明显上升。在该领域贡献最多的国家和研究者分别是美国和LI J团队。多黏菌素E是出现最多的关键词,并与肾毒性和药物代谢动力学关联度最高。研究领域包括了多黏菌素E剂量与肾毒性的关系、联合给药的抗菌活性及耐药性、治疗监测与药代动力学。群体药代动力学和相关的模型是最新的研究热点。结论本研究文献计量分析能更好地了解多黏菌素E TDM相关研究的现状,并对未来研究进行了展望,未来应加快推进多黏菌素E TDM室间质控和评价研究,完善质控方法。此外应对硫酸黏菌素群体药代动力学及剂量优化进行更多的探索研究。

Microwave-assisted Polymerization of ε-Caprolactone with Maleic Acid as Initiator and Drug Release Behavior of Ibuprofen-Poly(ε-caprolactone) System

Poly(e-caprolactone) (PCL) with weight-average molar mass over 10000 g/mol was synthesized by microwave-assisted ring-opening polymerization of e-caprolactone (e-CL) with maleic acid (MA) as initiator (2.45 GHz, 360 W, 85 min). Ibuprofen-PCL controlled release system was prepared directly by the ROP of e-CL in its mixture with ibuprofen. The release of ibuprofen from the system was sustained and steady.

基于“壁虎E护”平台的延续护理干预在肺结核咯血患者中的应用

目的探讨基于“壁虎E护”平台的延续护理在肺结核咯血患者中的应用效果。方法选取2021年10月-2022年3月笔者所在医院收治的30例肺结核咯血患者为对照组,选取2022年4月-9月收治的30例肺结核咯血患者为观察组。对照组采用常规出院宣教及院外随访,观察组在常规出院宣教的基础上实施基于“壁虎E护”平台的延续护理。比较2组自我护理能力、结核药物耐药率。结果干预后,观察组自我护理能力得分高于对照组(t=13.545,P<0.001),结核药物耐药率低于对照组(χ^(2)=4.706,P=0.030)。结论基于“壁虎E护”平台的延续性护理可促进肺结核咯血患者自我护理能力的提升,减少结核药物耐药的发生。

口腔溃疡疾病应用利多卡因联合维生素E用药治疗的效果

目的分析对口腔溃疡疾病采用利多卡因、维生素E联合药物治疗的效果。方法回顾性选取2022年2月—2023年2月菏泽医学专科学校附属医院口腔科收治的100例口腔溃疡患者为研究对象,根据治疗方式不同分为两组,对照组(n=50,西瓜霜治疗)和观察组(n=50,利多卡因、维生素E联合治疗)。比较两组治疗效果。结果治疗后,观察组总疗效率为96.00%,高于对照组的80.00%,差异有统计学意义(χ^(2)=6.061,P<0.05)。观察组的创面愈合时间、疼痛消失时间均短于对照组,差异有统计学意义(P<0.05)。治疗后,观察组白细胞介素-2水平高于对照组,白细胞介素-8、肿瘤坏死因子-α水平低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论针对口腔溃疡疾病,采用利多卡因、维生素E联合药物治疗,可提高用药治疗效果,促进创面更快愈合,缓解疼痛,有效改善炎性反应,且用药安全性高。

贵州部分地区猪源大肠杆菌耐药性分析及ESBLs基因型检测

为了解贵州地区规模养猪场大肠杆菌菌株耐药情况和ESBLs基因型的流行情况,试验采用CLSI推荐的方法对采自贵州省4个地区规模养猪场的164株大肠杆菌进行药物敏感性试验和产ESBLs菌的检测,并用PCR方法对TEM、SHV、OXA-1和CTX-M-1 4种常见ESBLs基因进行检测。结果显示,164株大肠杆菌对10种常用抗菌药物耐药率分别是头孢噻呋93.29%、氨苄西林87.19%、四环素86.59%、庆大霉素81.10%、链霉素53.66%、多黏菌素51.83%、环丙沙星53.05%、卡那霉素47.56%、金霉素34.76%和氟苯尼考21.95%,且大多为多重耐药,其中检测出ESBLs阳性菌株137株,阳性率为83.54%,各个地区的检出率不同;137株产ESBLs大肠杆菌中,TEM、SHV、OXA-1和CTX-M-1基因的检出率分别为90.51%、70.07%、51.82%和43.07%,且多为复合基因型耐药菌株,各地区的各种基因检出率不同。试验结果表明,贵州部分地区的猪源大肠杆菌耐药现象严重,ESBLs菌株的检出率很高,耐药基因的检出率也极高,且多为复合基因型耐药菌株,应加强当地产酶耐药菌的监测和研究,有效防制此类细菌引发的疾病。

宁夏地区牛源大肠埃希菌ESBLs检测及耐药性分析

为了解宁夏地区牛源超广谱β-内酰胺酶(ESBLs)的大肠埃希菌的耐药性、耐药特点及基因型分布,采用微量稀释法测定了16种抗菌药物对66株大肠埃希菌的MIC值,然后采用CLSI推荐的初筛及纸片确认方法对66株大肠埃希菌进行了ESBLs的检测,并采用PCR技术对ESBLs基因进行检测和初步分型。结果表明,大肠埃希菌对氯霉素、链霉素、四环素、多西环素、头孢和磺胺甲氧嘧啶的耐药率都比较高,而对阿米卡星、卡那霉素、多黏菌素、氟苯尼考及喹诺酮类药物则比较敏感。共检测出9株产超广谱β-内酰胺酶菌株,阳性率为13.64%,经PCR扩增、测序都为TEM型。结果显示,产ESBLs菌株多表现为多重耐药,对各种抗菌药物的耐药率均高于非ESBLs菌株。

耐甲氧西林金黄色葡萄球菌耐药性变迁及SCCmec基因分型

目的分析2011~2013年北京友谊医院耐甲氧西林金黄色葡萄球菌（MRSA）耐药谱变迁;了解其葡萄球菌盒式染体色mec（SCCmec）基因型分布特点。方法使用WHONET 5.6软件对2011至2013年间MRSA药物敏感结果进行数据分析。收集2013年3月至2013年10月首都医科大学附属北京友谊医院临床检验中心细菌室分离的非重复MRSA 30株,采用多重聚合酶链反应（PCR）对其进行SCCmec基因型分型。结果 2011~2013年3年的调查显示,临床标本中共分离出1 133株金黄色葡萄球菌检出MRSA 662株,检出率58.4%,3年检出率成逐渐上升趋势。MRSA检出标本来源于痰液及咽拭子最多,其次为血液、脓分泌物和尿液标本。MRSA主要分布在ICU、医保中心和急诊。662株MRSA对青霉素均为100%耐药,红霉素、克林霉素、庆大霉素、四环素耐药率均〉80%,环丙沙星、莫西沙星、左氧氟沙星耐药率97.2%~95%和96.7%~88.8%和97.2%~95.4%,对呋喃妥因、复方新诺明较敏感,耐药率〈10%,3年中未发现对万古霉素、替加环素,喹努普汀/达福普汀、利奈唑胺耐药菌。检出SCCmec III型有27株,检出率为90.0%;其余3株为未分型菌株,占10.0%。结论本次MRSA耐药监测中,其对万古霉素、利奈唑胺、替加环素均保持着高度敏感性,对呋喃妥因、复方新诺明较敏感,耐药率〈10%。其SCCmec基因分型以SCCmecⅢ型为主,与国内多数地区、医院报道的以SCCmecⅢ型为主相符。

四逆汤与维生素E抗血管内皮功能氧化损伤及防治家兔实验性动脉粥样硬化的比较研究

目的 :观察比较具有清除氧自由基作用的复方中药四逆汤与抗氧化剂维生素E抗血管内皮功能氧化损伤、防治家兔实验性动脉粥样硬化 (AS)的作用。方法 :运用喂饲高脂饲料造家兔实验性AS模型 ,随机分组处理 ,实验结束时 ,取主动脉及血样品 ,分析各组主动脉粥样斑块面积、脂代谢及血管内皮氧化损伤指标 (SOD活性、MDA含量、NO水平、ET浓度 )。结果 :四逆汤中、高剂量组和维生素E组的主动脉内膜脂质斑块面积与内皮氧化损伤变化 (除维生素E组的SOD活性外 )均明显轻于模型组 (P <0 0 5 ) ,四逆汤组的脂代谢紊乱指标也较模型组明显改善 (P均 <0 0 5 )。结论 :四逆汤抗血管内皮功能氧化损伤、防治AS的综合疗效较维生素E为优。

E-钙黏蛋白siRNA促进胃癌细胞SGC7901耐药与增殖

目的研究E-钙黏蛋白siRNA对胃癌细胞SGC7901化疗敏感性和增殖能力的影响,并对其相关机制进行初步探讨。方法用Lipofectamine 2000将E-钙黏蛋白siRNA及阴性对照序列转入细胞SGC7901,用MTT法检测细胞对药物的敏感性并观察细胞增殖能力。Western印迹法检测细胞E-钙黏蛋白、PTEN、AKT、p-AKT、BAX和BCL-2蛋白表达。结果 SGC7901细胞转染E-钙黏蛋白siRNA后显著抑制细胞E-钙黏蛋白蛋白表达(P<0.05)。转染E-钙黏蛋白siRNA后细胞对CDDP、5-FU、紫杉醇和ADR的IC50分别为(mg/L):4.375±0.199、6.855±0.780、2.530±0.259和0.368±0.042;阴性对照组分别为(mg/L):2.882±0.166、4.058±0.946、1.483±0.225和0.228±0.012,转染E-钙黏蛋白siRNA细胞对CDDP、5-FU、紫杉醇和ADR的IC50显著高于阴性对照组(P<0.05)。转染E-钙黏蛋白siRNA细胞增殖能力显著高于阴性对照组(P<0.05)。转染E-钙黏蛋白siRNA72 h后PTEN和BAX蛋白表达显著低于阴性对照组(P<0.05),而p-AKT和BCL-2蛋白表达显著高于阴性对照组(P<0.05)。结论干扰E-钙黏蛋白表达导致AKT通路的激活和对凋亡平衡的调控可能是促进SGC7901细胞耐药和增殖的一个机制。

E试验监测重症监护病房中400株革兰氏阴性杆菌的耐药性

目的 调查我院监护病房革兰氏阴性杆菌耐药状况及超广谱 β 内酰胺酶 (ESBLs)菌株的发生率 ,了解四年来革兰氏阴性菌对抗菌药物的耐药性变迁。方法 用E试验法测定 40 0株革兰氏阴性杆菌对11种抗生素的最低抑菌浓度 (MIC)。并用头孢他啶 /头孢他啶 +克拉维酸E试验酶试条检测细菌产ESBL的情况。结果 亚胺培南对所有受试菌保持最高抗菌活性 ,细菌耐药率仅为 7 5 % ;头孢哌酮 /舒巴坦、阿米卡星、哌拉西林 /三唑巴坦、头孢吡肟和头孢他啶仍有较高抗菌活性 ,耐药率分别为 16 0 %、2 0 0 %、2 2 5 %、2 3 %和 2 6 8% ;其它抗生素耐药率在 42 8%～ 46 8%之间。用头孢他啶 /头孢他啶 +克拉维酸筛选大肠埃希氏菌和肺炎克雷伯氏菌ESBLs产生菌 2 7株 ,检出率分别为 40 9%和 2 7 3 %。体外抗菌活性最强的是亚胺培南 ,所有大肠埃希氏菌和肺炎克雷伯氏菌ESBLs菌株都对之敏感。含酶抑制剂抗生素哌拉西林 /三唑巴坦和头孢哌酮 /舒巴坦对产ESBLs株保持较高体外抗菌活性 ,但 2 0 0 1年分离菌耐药率有所增加。四年资料相比 ,所测细菌对头孢哌酮 /舒巴坦耐药率由 1998～ 2 0 0 0年的 11%～ 14 %增加至 2 0 0 1年的 2 6% ,大肠埃希氏菌对环丙沙星耐药率由 1998～ 1999年的 45 2 %上升至 2 0 0 0～ 2 0 0 1年的 79 6%